Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

Fineline Cube Mar 25, 2026
Company Deals

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Fineline Cube Mar 25, 2026
Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Fineline Cube Mar 25, 2026
Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026
Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Fineline Cube Mar 25, 2026
Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Fineline Cube Mar 25, 2026
Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Fineline Cube Mar 25, 2026
Company Deals

Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs

Fineline Cube Feb 8, 2023

Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a...

Company Deals

Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development

Fineline Cube Feb 8, 2023

Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of...

Company Deals

Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research

Fineline Cube Feb 8, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...

Company

Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact

Fineline Cube Feb 7, 2023

Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial...

Company

Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth

Fineline Cube Feb 7, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...

Company Drug

Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial

Fineline Cube Feb 7, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...

Company Drug

Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study

Fineline Cube Feb 7, 2023

US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...

Company Deals

Lifetech Partners with Jenscare for Structural Heart Disease Devices

Fineline Cube Feb 7, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare...

Company Drug

Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...

Company

Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results

Fineline Cube Feb 6, 2023

US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...

Company Drug

Sanofi Reports Strong Q4 and Full-Year 2022 Financials with 7% Growth

Fineline Cube Feb 6, 2023

France’s Sanofi (EPA: SAN) released its financial report last week, showing turnover during Q4 and...

Company

Sanner Group Prepares to Open Second Manufacturing Facility in China

Fineline Cube Feb 6, 2023

Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to...

Company

Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi

Fineline Cube Feb 6, 2023

China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...

Digital Medical Device

Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment

Fineline Cube Feb 6, 2023

China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA)...

Company Digital

BeiGene Launches Mental Health Program for Cancer Patients

Fineline Cube Feb 6, 2023

China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...

Company Deals

AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics

Fineline Cube Feb 6, 2023

Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...

Company Drug

Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment

Fineline Cube Feb 6, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Forlong Biotechnology Secures Series A Funding for Protein Drug Development

Fineline Cube Feb 6, 2023

Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...

Company Deals

Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06

Fineline Cube Feb 6, 2023

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...

Posts pagination

1 … 540 541 542 … 640

Recent updates

  • Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market
  • MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333
  • Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance
  • Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer
  • China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

Company Deals

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.